GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adicet Bio Inc (NAS:ACET) » Definitions » Equity-to-Asset

Adicet Bio (Adicet Bio) Equity-to-Asset

: 0.82 (As of Dec. 2023)
View and export this data going back to 2020. Start your Free Trial

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Adicet Bio's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $170.18 Mil. Adicet Bio's Total Assets for the quarter that ended in Dec. 2023 was $207.30 Mil.

The historical rank and industry rank for Adicet Bio's Equity-to-Asset or its related term are showing as below:

ACET' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.74   Med: 0.82   Max: 0.89
Current: 0.82

During the past 6 years, the highest Equity to Asset Ratio of Adicet Bio was 0.89. The lowest was -0.74. And the median was 0.82.

ACET's Equity-to-Asset is ranked better than
70.5% of 1566 companies
in the Biotechnology industry
Industry Median: 0.66 vs ACET: 0.82

Adicet Bio Equity-to-Asset Historical Data

The historical data trend for Adicet Bio's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Array ( [0] => - [1] => -0.74 [2] => 0.71 [3] => 0.89 [4] => 0.88 [5] => 0.82 )
Adicet Bio Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Premium Member Only -0.74 0.71 0.89 0.88 0.82

Adicet Bio Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.88 0.87 0.86 0.84 0.82

Competitive Comparison

For the Biotechnology subindustry, Adicet Bio's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adicet Bio Equity-to-Asset Distribution

For the Biotechnology industry and Healthcare sector, Adicet Bio's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Adicet Bio's Equity-to-Asset falls into.



Adicet Bio Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Adicet Bio's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=170.175/207.295
=

Adicet Bio's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=170.175/207.295
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Adicet Bio  (NAS:ACET) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Adicet Bio Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Adicet Bio's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Adicet Bio (Adicet Bio) Business Description

Traded in Other Exchanges
Address
200 Clarendon Street, Floor 6, Boston, MA, USA, 02116
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. The company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. The company operates and manages its business as one reportable and operating segment, which is the business of research and development of allogeneic immunotherapies for cancer and other diseases.
Executives
Chen Schor director, officer: See Remarks PREDIX PHARMACEUTICALS HOLDINGS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Katie Peng director C/O ADICET BIO, INC., 200 BERKELEY STREET, 19TH FLOOR, BOSTON MA 02116
Steve Dubin director
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Carl L Gordon director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Don Healey officer: Chief Technology Officer 2635 TECHNOLOGY FOREST BOULEVARD, THE WOODLANDS TX 77381
Blake Aftab officer: Chief Scientific Officer C/O ADICET BIO, INC., 200 CLARENDON STREET, FLOOR 6, BOSTON MA 02116
Francesco Galimi officer: Chief Medical Officer 12930 VIA ESPERIA, DEL MAR CA 92014
Aya Jakobovits director 3135 HUTTON DRIVE, BEVERLY HILLS CA 90210
Orbimed Genesis Gp Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Andrew Sinclair director C/O SOLENO THERAPEUTICS INC., 1235 RADIO ROAD, SUITE 110, REDWOOD CITY CA 94065
Michael Kauffman director C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459
Bastiano Sanna director C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON MA 02210
Orbimed Capital Gp V Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Carrie Krehlik officer: Chief Human Resources Officer 6015 COLTON BLVD, OAKLAND CA 94611